These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35971310)

  • 1. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
    Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.
    Walter S; Langford O; Jimenez-Maggiora GA; Abdel-Latif S; Rissman RA; Grill JD; Karlawish J; Atri A; Bruschi S; Hussen K; Donohue MC; Marshall GA; Jicha G; Racke M; Turner RS; van Dyck CH; Venkatesh V; Yarasheski KE; Sperling R; Cummings J; Aisen PS; Raman R
    J Prev Alzheimers Dis; 2024; 11(5):1435-1444. PubMed ID: 39350391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
    Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
    J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.
    Feizpour A; Doré V; Doecke JD; Saad ZS; Triana-Baltzer G; Slemmon R; Maruff P; Krishnadas N; Bourgeat P; Huang K; Fowler C; Rainey-Smith SR; Bush AI; Ward L; Robertson J; Martins RN; Masters CL; Villemagne VL; Fripp J; Kolb HC; Rowe CC
    J Prev Alzheimers Dis; 2023; 10(4):828-836. PubMed ID: 37874105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
    JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.
    Jadick MF; Robinson T; Farrell ME; Klinger H; Buckley RF; Marshall GA; Vannini P; Rentz DM; Johnson KA; Sperling RA; Amariglio RE
    Neurology; 2024 Jun; 102(12):e209447. PubMed ID: 38810211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer's disease.
    Farrell ME; Thibault EG; Becker JA; Price JC; Healy BC; Hanseeuw BJ; Buckley RF; Jacobs HIL; Schultz AP; Chen CD; Sperling RA; Johnson KA
    Alzheimers Dement; 2024 Aug; 20(8):5434-5449. PubMed ID: 38988055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.